Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Acute Leukemia of Ambiguous Lineage: early-phase trial registry
1 of 3 indexed Refractory Acute Leukemia of Ambiguous Lineage trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Refractory Acute Leukemia of Ambiguous Lineage: 3 US clinical trials tracked, 1 recruiting.
Refractory Acute Leukemia of Ambiguous Lineage is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Oncology Group, running 1 of these trials.
Enrollment posture brief
Registry condition refractory-acute-leukemia-of-ambiguous-lineage
OPEN 1 | RECR 33% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Refractory Acute Leukemia of Ambiguous Lineage lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Acute Leukemia of Ambiguous Lineage on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Acute Leukemia of Ambiguous Lineage is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Fred Hutchinson Cancer Center
NCT04375631
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Children's Oncology Group
NCT05761171
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
NCT04898894
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Acute Leukemia of Ambiguous Lineage records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Acute Leukemia of Ambiguous Lineage trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Acute Leukemia of Ambiguous Lineage page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Refractory Acute Leukemia of Ambiguous Lineage trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Children's Oncology Group sponsors the most Refractory Acute Leukemia of Ambiguous Lineage trials on record, review their full trial history before evaluating a specific study. See Children's Oncology Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Acute Leukemia of Ambiguous Lineage condition card totals 3 registered trials; most-linked intervention Cytarabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.